Despite the effectiveness of CDK4/6 inhibitors in HR+ breast cancer, their preclinical and clinical effectiveness has been limited in other predominantly RB-proficient tumor types, such as in NSCLC, colorectal cancer and melanoma [200, 201]. Here, CDK4 is linked to breast carcinoma.